Clinical trials in Corbeil Essonnes – page 119

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Corbeil Essonnes at a glance

3 332

clinical trials

Research sites1

Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Breast cancer

Not yet recruiting

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cefazolin Sodium
Sponsor:University Hospital Of Clermont-Ferrand

Contact Research Centre

Systemic lupus erythematosus

Not yet recruiting

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Focal segmental glomerulosclerosis

Not yet recruiting

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Apellis Pharmaceuticals Inc.

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug

France

Participants:18–64 years · 65+ years
Substances:RADAMTS13
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Endometrial cancer+6

Not yet recruiting

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lirafugratinib hydrochloride
Sponsor:Elevar Therapeutics Inc.

Contact Research Centre

Homocystinuria

Not yet recruiting

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegtibatinase
Sponsor:Travere Therapeutics Inc.

Contact Research Centre

Allogenic stem cell transplantation+1

Not yet recruiting

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Unicancer

Contact Research Centre

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Cystic fibrosis

Not yet recruiting

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azithromycin
Sponsor:Centre Hospitalier Intercommunal Creteil

Contact Research Centre

Appendicitis

Not yet recruiting

Patient‑chosen treatment vs routine surgery for adult uncomplicated acute appendicitis: trial of amoxicillin‑clavulanic acid versus appendectomy

Registered drugNo placebo

Patient‑chosen treatment vs routine surgery for adult uncomplicated acute appendicitis: trial of amoxicillin‑clavulanic acid versus appendectomy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amoxicillin Sodium
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Myeloproliferative neoplasm

Not yet recruiting

Anakinra for patients with myeloproliferative neoplasms resistant to cytoreductive therapy: a study to improve treatment response

Registered drugNo placebo

Anakinra for patients with myeloproliferative neoplasms resistant to cytoreductive therapy: a study to improve treatment response

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anakinra
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

Glycemic Control Studies
Cardiovascular Risk Management
Weight Management Therapies

02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

Novel Drug Combinations
Maintenance Therapy Optimization
Minimal Residual Disease Studies

03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

Immunotherapy Development
Alternative Treatment Strategies
Disease Management Protocols

Back to France All countries